EGFR-TKI SENSITIZING MUTATION

Clinical trials for EGFR-TKI SENSITIZING MUTATION explained in plain language.

Never miss a new study

Get alerted when new EGFR-TKI SENSITIZING MUTATION trials appear

Sign up with your email to follow new studies for EGFR-TKI SENSITIZING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Higher dose tested for lung cancer patients not responding enough to standard treatment

Disease control Not yet recruiting

This study is testing whether increasing the dose of the drug firmonertinib can help patients with advanced lung cancer who have a specific genetic mutation. The trial is for people whose cancer has only stayed stable, not shrunk, after 8 weeks on the standard lower dose. Researc…

Matched conditions: EGFR-TKI SENSITIZING MUTATION

Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control

Last updated Mar 31, 2026 12:12 UTC

EGFR-TKI SENSITIZING MUTATION

Get alerted when new EGFR-TKI SENSITIZING MUTATION trials appear

Higher dose tested for lung cancer patients not responding enough to standard treatment